Radiology Room |
Ultrasound Room |
Surgery Room |
Laboratory Room |
Comprehensive Room |
Pediatrics Room |
Dental Room |
Medical operation instruments |
Hospital Furniture |
Medical supplies |
News Center
Innovative Infusion Catheter Targets Cancerous Tumors
A novel infusion catheter enables sideways perfusion, allowing physicians to precisely target and isolate areas within the body where the infused drugs need to be delivered.
The IsoFlow Infusion Catheter facilitates medication delivery by direct infusion of chemotherapy drugs to a targeted region of the body, such as a cancerous tumor. The IsoFlow is composed of a dual balloon catheter that isolates a specific treatment region from the blood flow, allowing the infusion of fluids into the region and the perfusion of blood past the region, to keep the blood flow intact during treatment. This isolation allows the physicians to increase drug concentrations at targeted sites while reducing systemic exposure, thereby improving efficacy and patient outcomes.
The IsoFlow catheter also enables sideways perfusion, which gives physicians the ability to deliver medications by using pressure to push the medication into the targeted area. During treatment, the IsoFlow catheter is inserted over a guide wire for precise positioning within a patient’s body. Once in place, medication is infused and isolated when both of the catheter’s balloons are simultaneously inflated via a liquid single-inflation lumen. The device also facilitates the lateral arterial chemo embolization (LACE) procedure. The IsoFlow Infusion Catheter is a product of Vascular Designs (San Jose, CA, USA), and has been approved by the US Food and Drug Administration (FDA).
“Directing treatment to specific locations increases the number of treatment options, allowing better access to tumors, and may reduce the discomfort to patients associated with the systemic application of chemotherapy,” said Robert Goldman, CEO of Vascular Designs and creator of the IsoFlow Infusion Catheter.
Guangzhou Jia Yu medical equipment Limited